{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T15:33:43Z","timestamp":1774107223533,"version":"3.50.1"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy driven by diverse genetic mutations that shape tumor progression, immune evasion, and clinical outcomes. While molecular profiling has improved AML classification, the precise impact of specific mutations on immune cell infiltration and dysregulation remains insufficiently understood. This review examines the immunologic consequences of common AML mutations\u2014including <jats:italic>FLT3-ITD<\/jats:italic>, <jats:italic>NPM1<\/jats:italic>, <jats:italic>DNMT3A<\/jats:italic>, <jats:italic>TP53<\/jats:italic>, <jats:italic>IDH1\/2<\/jats:italic>, and <jats:italic>NRAS<\/jats:italic>\u2014and their role in remodeling the immune microenvironment. We further explore the dynamic shifts in immune responses across different AML risk stratifications, emphasizing the balance between immune activation and suppression, which is influenced by specific genetic alterations. Additionally, we highlight the emerging potential of immunotherapies targeting neoepitopes derived from driver mutations, offering promising avenues to overcome immune escape and enhance anti-tumor immune responses. By integrating genetic mutations and immunologic insights, this review outlines a framework for developing more precise and effective immunotherapies for AML.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1635111","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T05:25:02Z","timestamp":1754889902000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The interaction between common genetic mutations in AML and the immune landscape: mechanisms and implications for immune response"],"prefix":"10.3389","volume":"16","author":[{"given":"Xuege","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanlu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0000000000000905","article-title":"Description of lymphocyte and cytokine profiles in individuals with acute myeloid leukemia associated with FLT3-ITD and NPM1 mutation status","volume":"34","author":"Reis","year":"2024","journal-title":"Eur J Cancer Prev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2016.08.005","article-title":"Molecular biomarkers in acute myeloid leukemia","volume":"31","author":"Prada-Arismendy","year":"2017","journal-title":"Blood Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1038\/s41467-023-41994-0","article-title":"Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia","volume":"14","author":"Mumme","year":"2023","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41551-020-00625-5","article-title":"CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia","volume":"5","author":"Xie","year":"2021","journal-title":"Nat Biomed engineering"},{"key":"B6","doi-asserted-by":"publisher","first-page":"216767","DOI":"10.1016\/j.canlet.2024.216767","article-title":"TP53 in MDS and AML: Biological and clinical advances","volume":"588","author":"Zhao","year":"2024","journal-title":"Cancer letters"},{"key":"B7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s12308-023-00536-9","article-title":"Effect of changes in lymphocyte subsets at diagnosis in acute myeloid leukemia on prognosis: association with complete remission rates and relapse free survivals","volume":"16","author":"Park","year":"2023","journal-title":"J hematopathology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1148748","article-title":"Combined flow cytometry natural killer immunophenotyping and KIR\/HLA-C genotyping reveal remarkable differences in acute myeloid leukemia patients, but suggest an overall impairment of the natural killer response","volume":"10","author":"Cianga","year":"2023","journal-title":"Front Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.665541","article-title":"Natural killer cell subpopulations and inhibitory receptor dynamics in myelodysplastic syndromes and acute myeloid leukemia","volume":"12","author":"Cianga","year":"2021","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179448","article-title":"Enhancing therapeutic efficacy of FLT3 inhibitors with combination therapy for treatment of acute myeloid leukemia","volume":"25","author":"Leifheit","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"104256","DOI":"10.1016\/j.exphem.2024.104256","article-title":"Immune control in acute myeloid leukemia","volume":"138","author":"Straube","year":"2024","journal-title":"Exp hematology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"111299","DOI":"10.1016\/j.biopha.2021.111299","article-title":"Targeting the NKG2D\/NKG2D-L axis in acute myeloid leukemia","volume":"137","author":"Wu","year":"2021","journal-title":"Biomedicine pharmacotherapy = Biomedecine pharmacotherapie"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2020459118","article-title":"High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome","volume":"118","author":"Chretien","year":"2021","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004794","article-title":"TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis","volume":"10","author":"Brauneck","year":"2022","journal-title":"J immunotherapy Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.686156","article-title":"PD-1 and TIGIT are highly co-expressed on CD8(+) T cells in AML patient bone marrow","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1297338","article-title":"Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency","volume":"15","author":"Flynn","year":"2024","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-018-0069-4","article-title":"Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients","volume":"8","author":"Jia","year":"2018","journal-title":"Blood Cancer J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-206946","article-title":"Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts","volume":"114","author":"Le Dieu","year":"2009","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI Insight"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000792","article-title":"Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival","volume":"4","author":"Br\u00fcck","year":"2020","journal-title":"Blood advances"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123376","article-title":"The role of T cell immunotherapy in acute myeloid leukemia","volume":"10","author":"Hao","year":"2021","journal-title":"Cells"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1000996","article-title":"The cytokine network in acute myeloid leukemia","volume":"13","author":"Luciano","year":"2022","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clml.2023.10.006","article-title":"SOHO state of the art updates and next questions: understanding and overcoming venetoclax resistance in hematologic Malignancies","volume":"24","author":"Forsberg","year":"2024","journal-title":"Clin lymphoma myeloma leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-023-01839-4","article-title":"CD8\u2009+\u2009T cell-based molecular subtypes with heterogeneous immune landscapes and clinical significance in acute myeloid leukemia","volume":"73","author":"Zhong","year":"2024","journal-title":"Inflammation Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012519","article-title":"Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation","volume":"139","author":"You","year":"2022","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2024.25.5.1777","article-title":"Prognostic effect of CTLA4\/LAG3 expression by T-cells subsets on acute myeloid leukemia patients","volume":"25","author":"El Dosoky","year":"2024","journal-title":"Asian Pacific J Cancer prevention: APJCP"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418792","article-title":"The profile and prognostic significance of bone marrow T-cell differentiation subsets in adult AML at diagnosis","volume":"15","author":"Sun","year":"2024","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000092","article-title":"The correlation between Flt3-ITD mutation in dendritic cells with TIM-3 expression in acute myeloid leukemia","volume":"3","author":"Shapoorian","year":"2021","journal-title":"Blood Sci (Baltimore Md)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s43018-022-00480-0","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry","year":"2023","journal-title":"Nat cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.980911","article-title":"FLT3LG and IFITM3P6 consolidate T cell activity in the bone marrow microenvironment and are prognostic factors in acute myelocytic leukemia","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01202-7","article-title":"Emerging DNA methylome targets in FLT3-ITD-positive acute myeloid leukemia: combination therapy with clinically approved FLT3 inhibitors","volume":"25","author":"Tecik","year":"2024","journal-title":"Curr Treat options Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03037-9","article-title":"MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutations","volume":"71","author":"Comont","year":"2022","journal-title":"Cancer immunology immunotherapy: CII"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20150642","article-title":"Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses","volume":"213","author":"Lau","year":"2016","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2346965","DOI":"10.1080\/16078454.2024.2346965","article-title":"Genetic mutations and immune microenvironment: unveiling the connection to AML prognosis","volume":"29","author":"Hu","year":"2024","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3892\/ol.2021.13169","article-title":"CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia","volume":"23","author":"Kaito","year":"2022","journal-title":"Oncol letters"},{"key":"B39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112823","article-title":"High PD-L1 expression predicts for worse outcome of leukemia patients with concomitant NPM1 and FLT3 mutations","volume":"20","author":"Brodsk\u00e1","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01162","article-title":"The interplay between the genetic and immune landscapes of AML: mechanisms and implications for risk stratification and therapy","volume":"9","author":"Mendez","year":"2019","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155005","article-title":"Serum levels of selected cytokines and soluble adhesion molecules in acute myeloid leukemia: Soluble receptor for interleukin-2 predicts overall survival","volume":"128","author":"Kupsa","year":"2020","journal-title":"Cytokine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e70006","DOI":"10.1002\/hem3.70006","article-title":"Activating mutations remodel the chromatin accessibility landscape to drive distinct regulatory networks in KMT2A-rearranged acute leukemia","volume":"8","author":"Zhang","year":"2024","journal-title":"HemaSphere"},{"key":"B44","doi-asserted-by":"publisher","first-page":"5576059","DOI":"10.1155\/2021\/5576059","article-title":"The emerging roles of CCN3 protein in immune-related diseases","volume":"2021","author":"Peng","year":"2021","journal-title":"Mediators inflammation"},{"key":"B45","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12974-020-02025-7","article-title":"CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis","volume":"17","author":"Naughton","year":"2020","journal-title":"J neuroinflammation"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1397330","article-title":"A loss of function mutation in SOCS2 results in increased inflammatory response of macrophages to TLR ligands and Staphylococcus aureus","volume":"15","author":"Guzylack-Piriou","year":"2024","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201396","article-title":"Regulation of Foxp3+ inducible regulatory T cell stability by SOCS2","volume":"190","author":"Knosp","year":"2013","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20235931","article-title":"IL-1\u03b2 Induces SOCS2 expression in human dendritic cells","volume":"20","author":"Sarajlic","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03574-5","article-title":"Immune characteristics and prognostic implications of mucosal-associated invariant T cells in acute myeloid leukemia","volume":"72","author":"Peng","year":"2023","journal-title":"Cancer immunology immunotherapy: CII"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008316","article-title":"Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML","volume":"7","author":"Issa","year":"2023","journal-title":"Blood advances"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current status and future perspectives in targeted therapy of NPM1-mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","author":"van der Lee","year":"2019","journal-title":"J Clin Invest"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e12168","DOI":"10.1002\/jev2.12168","article-title":"Tumour-derived small extracellular vesicles suppress CD8+ T cell immune function by inhibiting SLC6A8-mediated creatine import in NPM1-mutated acute myeloid leukaemia","volume":"10","author":"Peng","year":"2021","journal-title":"J extracellular vesicles"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179159","article-title":"Neoantigen-Specific T-cell immune responses: the paradigm of NPM1-mutated acute myeloid leukemia","volume":"22","author":"Forghieri","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00264","article-title":"B7-positive and B7-negative acute myeloid leukemias display distinct T cell maturation profiles, immune checkpoint receptor expression, and european leukemia net risk profiles","volume":"10","author":"Antohe","year":"2020","journal-title":"Front Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18326","article-title":"Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody","volume":"198","author":"Greiner","year":"2022","journal-title":"Br J haematology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01710","article-title":"PD-L1 is expressed and promotes the expansion of regulatory T cells in acute myeloid leukemia","volume":"11","author":"Dong","year":"2020","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2073050","DOI":"10.1080\/2162402X.2022.2073050","article-title":"NPM1 and DNMT3A mutations are associated with distinct blast immunophenotype in acute myeloid leukemia","volume":"11","author":"Ku\u017eelov\u00e1","year":"2022","journal-title":"Oncoimmunology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1433-6","article-title":"TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells","volume":"98","author":"Kikushige","year":"2013","journal-title":"Int J hematology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.12122\/j.issn.1673-4254.2022.03.01","article-title":"Prognostic implications and functional enrichment analysis of LTB4R in patients with acute myeloid leukemia","volume":"42","author":"Zhang","year":"2022","journal-title":"Nan fang yi ke da xue xue bao = J South Med University"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119696","article-title":"SPINK2 protein expression is an independent adverse prognostic marker in AML and is potentially implicated in the regulation of ferroptosis and immune response","volume":"24","author":"Pitts","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653030","article-title":"Study on the immune escape mechanism of acute myeloid leukemia with DNMT3A mutation","volume":"12","author":"Que","year":"2021","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05874-x","article-title":"DNMT3A-R882: a mutation with many paradoxes","volume":"103","author":"Jafari","year":"2024","journal-title":"Ann Hematol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4210","article-title":"DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling","volume":"22","author":"Guryanova","year":"2016","journal-title":"Nat Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12964-022-00978-1","article-title":"DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2\/NQO1 pathway","volume":"20","author":"Chu","year":"2022","journal-title":"Cell communication signaling: CCS"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmhg.2018.05.005","article-title":"Study of DNA methyl transferase 3A mutation in acute myeloid leukemic patients","volume":"19","author":"Elsayed","year":"2018","journal-title":"Egyptian J Med Human Genet."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.943688","article-title":"Clonal hematopoiesis-associated gene mutations affect acute graft-versus-host disease after hematopoietic stem cell transplantation in AML patients","volume":"29","author":"Wei","year":"2024","journal-title":"Ann transplantation"},{"key":"B68","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.immuni.2021.03.001","article-title":"Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes","volume":"54","author":"Ehx","year":"2021","journal-title":"Immunity"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1598","article-title":"miR-196b-TLR7\/8 signaling axis regulates innate immune signaling and myeloid maturation in DNMT3A-mutant AML","volume":"28","author":"Gamlen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2056677","article-title":"Somatic mutation-associated risk index based on lncRNA expression for predicting prognosis in acute myeloid leukemia","volume":"27","author":"Xu","year":"2022","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"B71","doi-asserted-by":"publisher","first-page":"20406207241257904","DOI":"10.1177\/20406207241257904","article-title":"Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine","volume":"15","author":"Zeidan","year":"2024","journal-title":"Ther Adv hematology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091282","article-title":"DNA methylation in regulatory T cell differentiation and function: challenges and opportunities","volume":"12","author":"Bai","year":"2022","journal-title":"Biomolecules"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2400620","DOI":"10.1080\/16078454.2024.2400620","article-title":"Elucidating the immune landscape and potential prognostic model in acute myeloid leukemia with TP53 mutation","volume":"29","author":"Zhu","year":"2024","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood advances"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043727","article-title":"The immuno-oncology and genomic aspects of DNA-hypomethylating therapeutics in acute myeloid leukemia","volume":"24","author":"Urabe","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1409210","article-title":"Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment","volume":"15","author":"Chomczyk","year":"2024","journal-title":"Front Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer discovery"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4661","article-title":"Transcriptional profiling demonstrates altered characteristics of CD8(+) cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia","volume":"11","author":"Abolhalaj","year":"2022","journal-title":"Cancer Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.717527","article-title":"Association analyses of TP53 mutation with prognosis, tumor mutational burden, and immunological features in acute myeloid leukemia","volume":"12","author":"Wen","year":"2021","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102434","article-title":"Are we moving the needle for patients with TP53-mutated acute myeloid leukemia","volume":"14","author":"Shallis","year":"2022","journal-title":"Cancers"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020731","article-title":"The role of the MDM2\/p53 axis in antitumor immune responses","volume":"143","author":"Brummer","year":"2024","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021950","article-title":"PLK4, a potential target against AML","volume":"142","author":"Palm-Apergi","year":"2023","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01487-9","article-title":"Isocitrate dehydrogenase mutations are associated with altered IL-1\u03b2 responses in acute myeloid leukemia","volume":"36","author":"Sunthankar","year":"2022","journal-title":"Leukemia"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e1528815","DOI":"10.1080\/2162402X.2018.1528815","article-title":"Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate","volume":"7","author":"Galluzzi","year":"2018","journal-title":"Oncoimmunology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283597","article-title":"D-2-hydroxyglutarate supports a tolerogenic phenotype with lowered major histocompatibility class II expression in non-malignant dendritic cells and acute myeloid leukemia cells","volume":"109","author":"Hammon","year":"2024","journal-title":"Haematologica"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e2023038","DOI":"10.4084\/MJHID.2023.038","article-title":"TP53-mutated myelodysplasia and acute myeloid leukemia","volume":"15","author":"Testa","year":"2023","journal-title":"Mediterr J Hematol Infect diseases"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2190432","article-title":"Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia","volume":"64","author":"Mustafa Ali","year":"2023","journal-title":"Leukemia lymphoma"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/s41467-023-37592-9","article-title":"Oncogenic drivers dictate immune control of acute myeloid leukemia","volume":"14","author":"Austin","year":"2023","journal-title":"Nat Commun"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01335-7","article-title":"Cells and signals of the leukemic microenvironment that support progression of T-cell acute lymphoblastic leukemia (T-ALL)","volume":"56","author":"Lyu","year":"2024","journal-title":"Exp Mol Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.811144","article-title":"Tumor microenvironment in acute myeloid leukemia: adjusting niches","volume":"13","author":"Menter","year":"2022","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1451486","article-title":"Immune-based subgroups uncover diverse tumor immunogenicity and implications for prognosis and precision therapy in acute myeloid leukemia","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0020","article-title":"Immune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells","volume":"4","author":"Nelde","year":"2023","journal-title":"Blood Cancer discovery"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26617","article-title":"Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia","volume":"10","author":"Forghieri","year":"2019","journal-title":"Oncotarget"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S303017","article-title":"IL-37 was involved in progress of acute myeloid leukemia through regulating IL-6 expression","volume":"13","author":"Wei","year":"2021","journal-title":"Cancer Manage Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0441-9","article-title":"CD8(+) T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia","volume":"33","author":"Radpour","year":"2019","journal-title":"Leukemia"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl4492","article-title":"Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy","volume":"386","author":"Kang","year":"2024","journal-title":"Sci (New York NY)"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00432-025-06244-4","article-title":"Mesenchymal stem cells in the bone marrow microenvironment: a double-edged sword for AML","volume":"151","author":"Saadh","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"217427","DOI":"10.1016\/j.canlet.2024.217427","article-title":"Driver mutation landscape of acute myeloid leukemia provides insights for neoantigen-based immunotherapy","volume":"611","author":"Jin","year":"2024","journal-title":"Cancer letters"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e70401","DOI":"10.1002\/cam4.70401","article-title":"A combinatorial functional precision medicine platform for rapid therapeutic response prediction in AML","volume":"13","author":"Sahib","year":"2024","journal-title":"Cancer Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"B104","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ajh.27583","article-title":"Maintenance therapy in AML: what is the future potential","author":"Goulart","year":"2025","journal-title":"Am J Hematol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2025.2461632","article-title":"FLT3-mutated AML: immune evasion through exosome-mediated mechanisms and innovative combination therapies targeting immune escape","volume":"25","author":"Saadh","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14383","article-title":"Advances and challenges in quizartinib-based FLT3 inhibition for acute myeloid leukemia: mechanisms of resistance and prospective combination therapies","volume":"114","author":"Bruzzese","year":"2025","journal-title":"Eur J Haematol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03837-6","article-title":"Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia","volume":"120","author":"Yamaguchi","year":"2024","journal-title":"Int J hematology"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-394395","article-title":"Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia","volume":"120","author":"Greiner","year":"2012","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12051086","article-title":"Hotspot DNA methyltransferase 3A (DNMT3A) and isocitrate dehydrogenase 1 and 2 (IDH1\/2) mutations in acute myeloid leukemia and their relevance as targets for immunotherapy","volume":"12","author":"Struckman","year":"2024","journal-title":"Biomedicines"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-496844","article-title":"Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)","volume":"122","author":"Greiner","year":"2013","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203443","article-title":"Immunotherapeutic potential of mutated NPM1 for the treatment of acute myeloid leukemia","volume":"16","author":"Greiner","year":"2024","journal-title":"Cancers"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-032839","article-title":"A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells","volume":"109","author":"Graf","year":"2007","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00642-8","article-title":"A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo","volume":"4","author":"Giannakopoulou","year":"2023","journal-title":"Nat Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1111\/tan.70058","article-title":"Selective HLA haplotype loss in npm1-positive acute myeloid leukaemia: A model of immunological escape","volume":"105","author":"Rombola","year":"2025","journal-title":"Hla"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1458449","article-title":"AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients","volume":"14","author":"Jung","year":"2024","journal-title":"Front Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Trans Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ajh.27584","article-title":"Treatment of relapsed\/refractory AML-novel treatment options including immunotherapy","author":"Moore","year":"2025","journal-title":"Am J hematology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1635111\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T05:25:04Z","timestamp":1754889904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1635111\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":119,"alternative-id":["10.3389\/fimmu.2025.1635111"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1635111","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"article-number":"1635111"}}